Navigation Links
Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds

Introduced at Informex 2008

REDWOOD CITY, Calif., Jan. 29 /PRNewswire/ -- Codexis(R), Inc., a private biotechnology company and leading developer of clean manufacturing processes, today introduced the Codex(TM) MicroCyp Plate, a research productivity tool which can be used by pharmaceutical companies to more rapidly identify and synthesize drug metabolites and novel drug lead candidates.

The Codex(TM) MicroCyp Plate is being introduced this week at Informex 2008 ( in New Orleans. It is based on a platform technology for preparing and identifying drug metabolites (substances produced during drug metabolism). These metabolites are generated by bacterial cytochrome P450 enzymes licensed by Codexis from the California Institute of Technology (see Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology from California Institute of Technology, August 29, 2007).

The research tool introduced today is based on a specific cytochrome (cyp) enzyme, 102A1, which metabolizes fatty acids in the microbe. Today's launch expands the Codexis research product family, adding metabolite screening and synthesis as well as lead diversification to a full suite of tools for improving pharmaceutical process development efficiency.

"This platform can be used by pharmaceutical companies to more efficiently identify and produce safer, more efficacious drugs earlier in the drug development process," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services. "Conventional methods for metabolite identification and production and lead diversification are difficult and time-consuming. Our customers now have an efficient way to make multiple compounds for testing at a reduced cost. They can also identify toxic metabolites before time and money are spent on problematic drug candidates."

Drug metabolites are produced by the body during the break-down (metabolism) of drugs. Primary metabolites are largely formed in the liver by human P450 enzymes to aid in elimination of a drug from the body. In some cases, metabolites can be toxic, while for other drugs, "active" metabolites have shown improved efficacy and lower toxicity than the administered drug substance. The US Food and Drug Administration now recommends metabolic characterization for all new investigational human therapeutics.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit

Contact. Justin Jackson,, Burns McClellan, 212-213-0006, or Lyn Christenson,, 650-421-8144.

SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Appoints Singapore Laboratories Managing Director
2. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
3. Bruce Pasternack Elected to Codexis Board
4. Codexis Opens Singapore Laboratory
5. Rothwell, Wolf Elected to Codexis Board
6. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
7. Novozymes Launches Enzyme to Reduce Acrylamide in Food
8. Enova Medical Launches Exos Corporation
9. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
10. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
11. ThirdBiotech Networking Group Launches
Post Your Comments:
(Date:12/1/2015)... Today the Allen Institute announced the opening of its ... Lake Union neighborhood, the city,s biotechnology hub. Located on ... North, the 270,000 square foot life sciences building is ... the Allen Institute for Cell Science. Paul ... Institute. "We started by building a map of the ...
(Date:12/1/2015)... Dec. 1, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... with MDRejuvena, Inc. ("the Company"). Proceeds from the loan ... of the Company,s Rejuvaphyl™ and daily skincare products. ... the MDRejuvena brand of high potency skincare products that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module ... power of SICM to an AFM. , Park SICM benefits virtually all materials ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):